Validation of liquid biopsy for ESR1-mutation analysis in hormone-sensitive breast cancer: a pooled meta-analysis

被引：5
作者：
Najim, Omar [1 ,2 ]
Papadimitriou, Konstantinos [1 ,2 ,3 ]
Broeckx, Glenn [1 ,2 ,4 ]
Huizing, Manon [2 ,5 ]
Tjalma, Wiebren [1 ,2 ,6 ]
机构：
[1] Univ Antwerp, Univ Antwerp Hosp, Multidisciplinary Breast Clin, Edegem, Belgium
[2] Univ Antwerp, Fac Med, Edegem, Belgium
[3] Antwerp Univ Hosp, Dept Med Oncol, Edegem, Belgium
[4] Antwerp Univ Hosp, Dept Pathol, Edegem, Belgium
[5] Antwerp Univ Hosp, Biobank, Edegem, Belgium
[6] Univ Antwerp, Antwerp Univ Hosp, Dept Obstet & Gynecol, Unit Gynecol Oncol, Edegem, Belgium
来源：
FRONTIERS IN ONCOLOGY | 2023年 / 13卷
关键词：
ESR1; liquid biopsy; next-generation sequencing; digital PCR; metastasized breast cancer; CIRCULATING TUMOR DNA; ACTIVATING ESR1 MUTATIONS; ACQUIRED-RESISTANCE; PLASMA; EVOLUTION; EMERGENCE; THERAPY;
D O I：
10.3389/fonc.2023.1221773
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Several retrospective and prospective studies have shown that genomic alterations in Estrogen-receptor one (ESR1) can be characterized not only in tissue samples but also by sequencing circulating tumor DNA (ctDNA) in liquid biopsy. Therefore, liquid biopsy is a potential noninvasive surrogate for tissue biopsy. This meta-analysis was designed to compare the prevalence of ESR 1 mutation detected with liquid biopsy and tissue biopsy. A pooled meta-analysis of studies published between 1 January 2007 and 1 March 2021 was conducted regarding the methodologies used for ESR1 mutation analysis. Liquid biopsy is a valid, inexpensive, and attractive noninvasive alternative to tumor biopsies for the identification of ESR1 mutations. Liquid biopsy for ESR 1 analysis would facilitate regular testing, allowing monitoring of the sensitivity to ET and guiding treatment strategies.
引用
收藏
页数：12
相关论文
共 60 条
  • [1] Circulating Tumor Cells: Liquid Biopsy of Cancer
    Alix-Panabieres, Catherine
    Pantel, Klaus
    [J]. CLINICAL CHEMISTRY, 2013, 59 (01) : 110 - 118
  • [2] ESR1 mutations: Moving towards guiding treatment decision-making in metastatic breast cancer patients
    Angus, Lindsay
    Beije, Nick
    Jager, Agnes
    Martens, John W. M.
    Sleijfer, Stefan
    [J]. CANCER TREATMENT REVIEWS, 2017, 52 : 33 - 40
  • [3] The Implications of Clonal Genome Evolution for Cancer Medicine
    Aparicio, Samuel
    Caldas, Carlos
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2013, 368 (09) : 842 - 851
  • [4] Estrogen receptor (ESR1) mutation in bone metastases from breast cancer
    Bartels, Stephan
    Christgen, Matthias
    Luft, Angelina
    Persing, Sascha
    Joedecke, Kai
    Lehmann, Ulrich
    Kreipe, Hans
    [J]. MODERN PATHOLOGY, 2018, 31 (01) : 56 - 61
  • [5] Detection of Cancer DNA in Plasma of Patients with Early-Stage Breast Cancer
    Beaver, Julia A.
    Jelovac, Danijela
    Balukrishna, Sasidharan
    Cochran, Rory L.
    Croessmann, Sarah
    Zabransky, Daniel J.
    Wong, Hong Yuen
    Toro, Patricia Valda
    Cidado, Justin
    Blair, Brian G.
    Chu, David
    Burns, Timothy
    Higgins, Michaela J.
    Stearns, Vered
    Jacobs, Lisa
    Habibi, Mehran
    Lange, Julie
    Hurley, Paula J.
    Lauring, Josh
    VanDenBerg, Dustin A.
    Kessler, Jill
    Jeter, Stacie
    Samuels, Michael L.
    Maar, Dianna
    Cope, Leslie
    Cimino-Mathews, Ashley
    Argani, Pedram
    Wolff, Antonio C.
    Park, Ben Ho
    [J]. CLINICAL CANCER RESEARCH, 2014, 20 (10) : 2643 - 2650
  • [6] Prognostic effect of estrogen receptor status across age in primary breast cancer
    Bentzon, Niels
    Duering, Maria
    Rasmussen, Birgitte Bruun
    Mouridsen, Henning
    Kroman, Niels
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2008, 122 (05) : 1089 - 1094
  • [7] Bidard FC, 2020, J CLIN ONCOL, V38
  • [8] Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial
    Bidard, Francois-Clement
    Kaklamani, Virginia G.
    Neven, Patrick
    Streich, Guillermo
    Montero, Alberto J.
    Forget, Frederic
    Mouret-Reynier, Marie-Ange
    Sohn, Joo Hyuk
    Taylor, Donatienne
    Harnden, Kathleen K.
    Khong, Hung
    Kocsis, Judit
    Dalenc, Florence
    Dillon, Patrick M.
    Babu, Sunil
    Waters, Simon
    Deleu, Ines
    Saenz, Jose A. Garcia
    Bria, Emilio
    Cazzaniga, Marina
    Lu, Janice
    Aftimos, Philippe
    Cortes, Javier
    Liu, Shubin
    Tonini, Giulia
    Laurent, Dirk
    Habboubi, Nassir
    Conlan, Maureen G.
    Bardia, Aditya
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (28) : 3246 - +
  • [9] Detection of PIK3CA mutations in circulating free DNA in patients with breast cancer
    Board, Ruth E.
    Wardley, Andrew M.
    Dixon, J. Michael
    Armstrong, Anne C.
    Howell, Sacha
    Renshaw, Lorna
    Donald, Emma
    Greystoke, Alastair
    Ranson, Malcolm
    Hughes, Andrew
    Dive, Caroline
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2010, 120 (02) : 461 - 467
  • [10] ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer
    Brett, Jamie O.
    Spring, Laura M.
    Bardia, Aditya
    Wander, Seth A.
    [J]. BREAST CANCER RESEARCH, 2021, 23 (01)
123456